The Effectiveness of Ologen® Collagen Matrix in Preventing Intraocular Pressure (IOP) Spikes After Ahmed Glaucoma Valve Surgery (AGV-FP7)

Sponsor
The New York Eye & Ear Infirmary (Other)
Overall Status
Terminated
CT.gov ID
NCT02990143
Collaborator
(none)
30
1
2
47
0.6

Study Details

Study Description

Brief Summary

The purpose of this study is to investigate whether placing Ologen over the posterior plate of the Ahmed glaucoma drainage device during initial implantation will allow the formation of a thinner capsule, and decrease the incidence and/or the extent of IOP elevation during the postoperative period.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Ologen
Phase 2

Detailed Description

Uncontrolled glaucoma may require surgical intervention. Glaucoma drainage implants such as AGV-FP7 are in wide use upon glaucoma and comprehensive surgeons. The success of aqueous shunt surgery depends on the formation and maintenance of a thin permeable capsule around the posterior plate of the aqueous shunt. Encapsulated bleb formation, where the capsule is thick and elevated, is a common cause of drainage failure in the early post-operative period. This finding is usually accompanied by elevated intraocular pressure (IOP), which requires additional intervention, often surgical and therefore reduces the success rate of the initial surgery.

Recently, a biodegradable porous collagen-glycosaminoglycan copolymer matrix implant (Ologen), has become available for glaucoma surgery. This device is constructed so as to minimize random growth of fibroblasts and instead to allow them to grow through the pores in the matrix. Ologen® CM,a biodegradable scaffold matrix, induces a regenerative non-scarring wound healing process without using anti-fibrotic agents.

This study is to investigate whether placing Ologen over the posterior plate of the Ahmed glaucoma drainage device during initial implantation will allow the formation of a thinner capsule, and decrease the incidence and/or the extent of IOP elevation during the postoperative period.

Study Design

Study Type:
Interventional
Actual Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
The Effectiveness of Ologen® Collagen Matrix in Preventing Intraocular Pressure (IOP) Spikes After Ahmed Glaucoma Valve Surgery (AGV-FP7)
Actual Study Start Date :
Jan 15, 2014
Actual Primary Completion Date :
Dec 15, 2017
Actual Study Completion Date :
Dec 15, 2017

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Glaucoma Drainage implant no Ologen

The first group will use the routine technique for glaucoma drainage implant without placement of Ologen.

Active Comparator: Glaucoma Drainage implant with Ologen

the second group will undergo the same procedure but will have the Ologen placed and secured over the plate of the AGV-FP7, under the conjunctiva, during the surgery.

Procedure: Ologen
Ologen® CM,a biodegradable scaffold matrix, induces a regenerative non-scarring wound healing process without using anti-fibrotic agents.

Outcome Measures

Primary Outcome Measures

  1. The Effectiveness of ologen® Collagen Matrix in preventing intraocular pressure (IOP) spikes after Ahmed Glaucoma Valve Surgery (AGV-FP7) [1 year]

    Ologen over the posterior plate of the Ahmed glaucoma drainage device during initial implantation will allow the formation of a thinner capsule, and decrease the incidence and/or the extent of IOP elevation during the postoperative period.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age ≥18 years.

  • Uncontrolled treated glaucoma requiring AGV-FP7 surgery.

  • Subject must be able and willing to cooperate with investigation plan.

  • Subject must be able and willing to complete postoperative follow-up requirements

  • Subject must be willing to sign informed consent form

Exclusion Criteria:
  • Known allergic reaction to porcine collagen

  • History of uveitis

  • Corneal opacity or irregularity, preventing visualization of patency of tip of tube or accurate applanation

  • History of scleral buckle

Contacts and Locations

Locations

Site City State Country Postal Code
1 New York Eye and Ear Infirmary New York New York United States 10003

Sponsors and Collaborators

  • The New York Eye & Ear Infirmary

Investigators

  • Principal Investigator: Noga Harizman, MD, NY Eye Ear

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
The New York Eye & Ear Infirmary
ClinicalTrials.gov Identifier:
NCT02990143
Other Study ID Numbers:
  • 13.33
First Posted:
Dec 13, 2016
Last Update Posted:
Mar 17, 2021
Last Verified:
Mar 1, 2021
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 17, 2021